BeOne Medicines (ONC) Total Current Liabilities (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Total Current Liabilities of $1.8 billion for Q1 2026, down 8.68% year-over-year from $2.0 billion in Q1 2025, and down 0.95% quarter-over-quarter from $1.8 billion in Q4 2025.
BeOne Medicines (ONC) Total Current Liabilities (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Total Current Liabilities for 12 consecutive years, with $1.8 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities fell 8.68% year-over-year to $1.8 billion; the TTM figure through Mar 2026 stood at $1.8 billion (down 8.68% YoY), while the FY2025 annual figure was $1.8 billion, down 17.43% from the prior year.
- Total Current Liabilities slipped to $1.8 billion in Q1 2026 per ONC's latest filing, from $1.8 billion in the prior quarter.
- Across five years, Total Current Liabilities topped out at $2.4 billion in Q3 2025 and bottomed at $917.4 million in Q4 2022.
- Historically, Total Current Liabilities has averaged $1.7 billion across 5 years, with a median of $1.8 billion in 2026.
- Annual changes were most pronounced in 2022 — Total Current Liabilities slumped 42.65% — and 2023, when it jumped 97.32%.
- BeOne Medicines' Total Current Liabilities stood at $917.4 million in 2022, then surged by 97.32% to $1.8 billion in 2023, then climbed by 22.36% to $2.2 billion in 2024, then declined by 17.43% to $1.8 billion in 2025, then slipped by 0.95% to $1.8 billion in 2026.
- Business Quant data shows ONC's Total Current Liabilities at $1.8 billion in Q1 2026, $1.8 billion in Q4 2025, and $2.4 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 283.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.12 Bn |
| Mar 31, 2026 | 1.81 Bn |
| Dec 31, 2025 | 1.83 Bn |
| Sep 30, 2025 | 2.37 Bn |
| Jun 30, 2025 | 2.21 Bn |
| Mar 31, 2025 | 1.98 Bn |
| Dec 31, 2024 | 2.21 Bn |
| Sep 30, 2024 | 2.03 Bn |
| Jun 30, 2024 | 1.94 Bn |
| Mar 31, 2024 | 1.88 Bn |
| Dec 31, 2023 | 1.81 Bn |
| Sep 30, 2023 | 1.28 Bn |
| Jun 30, 2023 | 1.41 Bn |
| Mar 31, 2023 | 1.25 Bn |
| Dec 31, 2022 | 917.35 Mn |
| Sep 30, 2022 | 1.41 Bn |
| Jun 30, 2022 | 1.40 Bn |
| Mar 31, 2022 | 1.38 Bn |
| Dec 31, 2021 | 1.60 Bn |
| Sep 30, 2021 | 1.30 Bn |